MUC16 and ovarian cancer: While several biomarkers/panels of biomarkers with reported higher sensitivities and specificities than CA125 are being investigated, none of these have improved upon the low efficacy of the measurement of CA125 levels in distinguishing ovarian cancer patients from controls during the asymptomatic stages of the disease [4-10].